Delphi method was employed to establish consensus guidelines describing fluorescence imaging (MolecuLight i:X) use
96% reported that imaging-informed treatment plans led to improved wound healing
Guidelines provided will help to standardize use of fluorescence imaging among wound care providers
23% increase in 12 week wound healing rate
33% decrease in antibiotic prescribing
47% decrease in antimicrobial spending per wound
25% decrease in wound area over 4 weeks with the elimination of bacterial fluorescence from wounds
A positive healing trajectory was associated with the implementation of fluorescence imaging (i:X)
All wounds where fluorescence signal from bacteria was eradicated healed within 2-6 weeks
MolecuLight i:X
is designated as a
MolecuLight is a proud corporate member of:
© 2021
The MolecuLight® i:X Imaging Device is approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X Imaging Device has received FDA clearance.